Tags

Type your tag names separated by a space and hit enter

Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
Diabetes Metab Res Rev. 2002 Nov-Dec; 18(6):484-90.DM

Abstract

BACKGROUND

Postprandial hyperlipemia and small, dense LDL particles are features of dyslipidemia in type 2 diabetes. The purpose of this study was (1) to determine whether the oral insulinotropic drugs, nateglinide and glibenclamide, can overcome the defect of insulin action to suppress the hepatic VLDL release after a meal and decrease the postprandial lipemia and (2) to evaluate the acute effect of postprandial hypertriglyceridemia on LDL particle size in subjects with type 2 diabetes.

METHODS

Forty-three subjects with type 2 diabetes and mean baseline HbA(1c) 7.6% (95% CI 7.3 to 7.9) were treated with nateglinide 120 mg three times daily or glibenclamide 5 mg once or twice daily for 12 weeks in a double-blind randomised trial. Insulin, glucose, and lipoprotein responses to a mixed fat-rich meal were determined for 8 h postprandially at baseline and at 12 weeks on-trial.

RESULTS

Nateglinide and glibenclamide significantly augmented the maximal response in serum insulin at 60 min postprandially compared with the response without the drug [additional increase 25.0 mU/l (95% CI 11.2-38.8) p = 0.001 and 12.5 mU/l (95% CI 4.6-20.3) p = 0.003, respectively] and reduced hyperglycemia. Neither drug affected fasting or postprandial lipid or lipoprotein levels. LDL size did not significantly change in the 8-h postprandial period.

CONCLUSIONS

Although nateglinide and glibenclamide increase postprandial insulin secretion and attenuate hyperglycemia, they do not alleviate postprandial lipemia in subjects with type 2 diabetes and good glycemic control. Although small LDL particle size is associated with chronic hypertriglyceridemia, LDL size does not change during acute postprandial hypertriglyceridemia.

Authors+Show Affiliations

Helsinki University Central Hospital, Helsinki, Finland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12469362

Citation

Vakkilainen, Juha, et al. "Effects of Nateglinide and Glibenclamide On Postprandial Lipid and Glucose Metabolism in Type 2 Diabetes." Diabetes/metabolism Research and Reviews, vol. 18, no. 6, 2002, pp. 484-90.
Vakkilainen J, Mero N, Schweizer A, et al. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. Diabetes Metab Res Rev. 2002;18(6):484-90.
Vakkilainen, J., Mero, N., Schweizer, A., Foley, J. E., & Taskinen, M. R. (2002). Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. Diabetes/metabolism Research and Reviews, 18(6), 484-90.
Vakkilainen J, et al. Effects of Nateglinide and Glibenclamide On Postprandial Lipid and Glucose Metabolism in Type 2 Diabetes. Diabetes Metab Res Rev. 2002 Nov-Dec;18(6):484-90. PubMed PMID: 12469362.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. AU - Vakkilainen,Juha, AU - Mero,Niina, AU - Schweizer,Anja, AU - Foley,James E, AU - Taskinen,Marja-Riitta, PY - 2002/12/7/pubmed PY - 2003/7/18/medline PY - 2002/12/7/entrez SP - 484 EP - 90 JF - Diabetes/metabolism research and reviews JO - Diabetes Metab Res Rev VL - 18 IS - 6 N2 - BACKGROUND: Postprandial hyperlipemia and small, dense LDL particles are features of dyslipidemia in type 2 diabetes. The purpose of this study was (1) to determine whether the oral insulinotropic drugs, nateglinide and glibenclamide, can overcome the defect of insulin action to suppress the hepatic VLDL release after a meal and decrease the postprandial lipemia and (2) to evaluate the acute effect of postprandial hypertriglyceridemia on LDL particle size in subjects with type 2 diabetes. METHODS: Forty-three subjects with type 2 diabetes and mean baseline HbA(1c) 7.6% (95% CI 7.3 to 7.9) were treated with nateglinide 120 mg three times daily or glibenclamide 5 mg once or twice daily for 12 weeks in a double-blind randomised trial. Insulin, glucose, and lipoprotein responses to a mixed fat-rich meal were determined for 8 h postprandially at baseline and at 12 weeks on-trial. RESULTS: Nateglinide and glibenclamide significantly augmented the maximal response in serum insulin at 60 min postprandially compared with the response without the drug [additional increase 25.0 mU/l (95% CI 11.2-38.8) p = 0.001 and 12.5 mU/l (95% CI 4.6-20.3) p = 0.003, respectively] and reduced hyperglycemia. Neither drug affected fasting or postprandial lipid or lipoprotein levels. LDL size did not significantly change in the 8-h postprandial period. CONCLUSIONS: Although nateglinide and glibenclamide increase postprandial insulin secretion and attenuate hyperglycemia, they do not alleviate postprandial lipemia in subjects with type 2 diabetes and good glycemic control. Although small LDL particle size is associated with chronic hypertriglyceridemia, LDL size does not change during acute postprandial hypertriglyceridemia. SN - 1520-7552 UR - https://www.unboundmedicine.com/medline/citation/12469362/Effects_of_nateglinide_and_glibenclamide_on_postprandial_lipid_and_glucose_metabolism_in_type_2_diabetes_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=1520-7552&date=2002&volume=18&issue=6&spage=484 DB - PRIME DP - Unbound Medicine ER -